Skip Navigation

Cardiovascular Research 1998 37(3):700-709; doi:10.1016/S0008-6363(97)00244-7
© 1998 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Erratum (v40,p608)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Miura, T.
Right arrow Articles by Shimamoto, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miura, T.
Right arrow Articles by Shimamoto, K.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1998, European Society of Cardiology

Effect of protein kinase C inhibitors on cardioprotection by ischemic preconditioning depends on the number of preconditioning episodes

Tetsuji Miuraa,*, Toshiro Miurab, Shuji Kawamurab, Mahiko Gotoa, Jun Sakamotoa, Akihito Tsuchidaa, Masunori Matsuzakib and Kazuaki Shimamotoa

aSecond Department of Internal Medicine, Sapporo Medical University, School of Medicine, South-1 West-16, Chuo-ku, Sapporo 060, Japan
bSecond Department of Internal Medicine, Yamaguchi University, School of Medicine, Ube, Japan

* Corresponding author. Tel.: +(81-11) 611 2111X3225; fax: (+81-11) 644 7958; e-mail: miura@samped.ac.jp

Objectives: This study examined the possibility that the role of PKC and PC, and thus the response to PFC inhibitors, may differ depending on how many ischemic episodes are employed to precondition the heart. Methods: In the first series of experiments, myocardial infarct was induced by 30 min of coronary occlusion and 3 h of reperfusion in the rabbit. Infarct size was determined by tetrazolium staining and expressed as a percentage of area at risk (%IS/AR). Prior to the 30-min ischemia, rabbits were subjected to no PC, single PC (i.e., PC with an episode of 5 min ischemia/5 min reperfusion), and repetitive PC (2 cycles of 5 min ischemia/5 min reperfusion) with or without one of three treatments: polymyxin B (PolyB), staurosporine (Stauro), and 8-sulfophenylthephylline (SPT). In the second series of experiments, the rabbits received 5 min of coronary occlusion after repetitive PC with or without PolyB or Stauro treatment. Then, myocardial tissue in the ischemic region was sampled for assay of PKC activity. Untreated rabbits served as controls. Results: Single and repetitive PC limited %IS/AR to the same extent (%IS/AR=9.8±1.9 and 10.4±2.3, both p<0.05, vs. the control value of 44.5±3.4), and single PC was blocked by PolyB (%IS/AR=43.9±2.7) and Stauro (%IS/AR=31.5±3.2). Although the protocol of PolyB injection maintained the plasma PolyB level during sustained ischemia well above its Ki for PKC, this agent and also Stauro failed to abolish the protection by repetitive PC (%IS/AR=21.6±3.0 and 11.4±4.3, respectively). SPT, an adenosine receptor antagonist, not only blocked single PC (%IS/AR=44.4±4.4) but also attenuated protection by repetitive PC (%IS/AR=28.3±3.6). Infarct sizes in non-preconditioned hearts were not modified by PolyB, Stauro, or SPT. The ratio of membrane fraction PKC activity to cytosolic fraction PKC activity was elevated by repetitive PC plus 5 min ischemia, and this change in PKC was inhibited in hearts given PolyB and Stauro. Conclusions: In contrast to single PC, repetitive PC protects the heart against infarction even when PolyB and Stauro are administered to inhibit PKC during ischemic insult. This difference may be attributable to a PKC-independent mechanism, in which the adenosine receptor may be partly involved.

KEYWORDS Protein kinase C; Adenosine receptor; Myocardial infarction; Rabbit



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cardiovasc ResHome page
K. Watanabe, H. Yaoita, K. Ogawa, M. Oikawa, K. Maehara, and Y. Maruyama
Attenuated cardioprotection by ischemic preconditioning in coronary stenosed heart and its restoration by carvedilol
Cardiovasc Res, August 1, 2006; 71(3): 537 - 547.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
M. Fujii and D. J. Chambers
Myocardial protection with intermittent cross-clamp fibrillation: does preconditioning play a role?
Eur. J. Cardiothorac. Surg., December 1, 2005; 28(6): 821 - 831.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Ii, H. Nishimura, A. Iwakura, A. Wecker, E. Eaton, T. Asahara, and D. W. Losordo
Endothelial Progenitor Cells Are Rapidly Recruited to Myocardium and Mediate Protective Effect of Ischemic Preconditioning via "Imported" Nitric Oxide Synthase Activity
Circulation, March 8, 2005; 111(9): 1114 - 1120.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
D. Obal, N. C. Weber, K. Zacharowski, O. Toma, S. Dettwiler, J. I. Wolter, M. Kratz, J. Mullenheim, B. Preckel, and W. Schlack
Role of protein kinase C-{varepsilon} (PKC{varepsilon}) in isoflurane-induced cardioprotection
Br. J. Anaesth., February 1, 2005; 94(2): 166 - 173.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. Das, R. Ockaili, F. Salloum, and R. C. Kukreja
Protein kinase C plays an essential role in sildenafil-induced cardioprotection in rabbits
Am J Physiol Heart Circ Physiol, April 1, 2004; 286(4): H1455 - H1460.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Tsuchida, T. Miura, M. Tanno, J. Sakamoto, T. Miki, A. Kuno, T. Matsumoto, Y. Ohnuma, Y. Ichikawa, and K. Shimamoto
Infarct size limitation by nicorandil: Roles of mitochondrial KATP channels, sarcolemmal KATP channels, and protein kinase C
J. Am. Coll. Cardiol., October 16, 2002; 40(8): 1523 - 1530.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Ohnuma, T. Miura, T. Miki, M. Tanno, A. Kuno, A. Tsuchida, and K. Shimamoto
Opening of mitochondrial KATP channel occurs downstream of PKC-epsilon activation in the mechanism of preconditioning
Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H440 - H447.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
A. Nakano, C. P. Baines, S. O. Kim, S. L. Pelech, J. M. Downey, M. V. Cohen, and S. D. Critz
Ischemic Preconditioning Activates MAPKAPK2 in the Isolated Rabbit Heart : Evidence for Involvement of p38 MAPK
Circ. Res., February 4, 2000; 86(2): 144 - 151.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
T. Miura, Y. Liu, H. Kita, T. Ogawa, and K. Shimamoto
Roles of mitochondrial ATP-sensitive K channels and PKC in anti-infarct tolerance afforded by adenosine A1 receptor activation
J. Am. Coll. Cardiol., January 1, 2000; 35(1): 238 - 245.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. M. Fryer, J. E. J. Schultz, A. K. Hsu, and G. J. Gross
Importance of PKC and tyrosine kinase in single or multiple cycles of preconditioning in rat hearts
Am J Physiol Heart Circ Physiol, April 1, 1999; 276(4): H1229 - H1235.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.